5-[1,2,3]thiadiazol-4-yl-thiophene-2-sulfonyl chloride | 320421-81-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-[1,2,3]thiadiazol-4-yl-thiophene-2-sulfonyl chloride
• 英文别名: 5-(1,2,3-thiadiazol-4-yl)-2-thiophenesulfonyl chloride；5-(1,2,3-Thiadiazol-4-YL)-2-thiophenesulfonoyl chloride；5-(thiadiazol-4-yl)thiophene-2-sulfonyl chloride
• CAS: 320421-81-6
• 化学式: C₆H₃ClN₂O₂S₃
• mdl: MFCD00793708
• 分子量: 266.753
• InChiKey: YLMRFUGVQGEIMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  125
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-[1,2,3]thiadiazol-4-yl-thiophene-2-sulfonyl chloride 在 盐酸 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 4.5h， 生成 N-[(3R)-1-cyano-3-pyrrolidinyl]-5-(1,2,3-thiadiazol-4-yl)-2-thiophenesulfonamide
  参考文献：
  名称：

  [EN] CATHEPSIN C INHIBITORS
  [FR] INHIBITEURS DE LA CATHEPSINE C

  摘要：

  本文披露的是以下化合物的结构（I）；或其盐，其中Ar是单环杂芳环、双环杂芳环或双环杂环烷基芳环。

  公开号：

  WO2009129370A1

文献信息

• N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES
  申请人：GRIFFIOEN Gerard

  公开号：US20100197703A1

  公开（公告）日：2010-08-05

  This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides methods for making such derivatives, and pharmaceutical compositions including such derivatives together with pharmaceutically acceptable excipients.

  该发明提供了噻唑基哌嗪衍生物，以及包括苯基和苄基噻唑基哌啶衍生物的N-磺酰杂环衍生物，以及其药学上可接受的盐，这些是用于治疗α-突触核蛋白病的有效活性成分，如帕金森病、弥漫性小体病、创伤性脑损伤、肌萎缩侧索硬化症、尼曼-匹克病、哈勒沃登-施帕茨综合征、唐氏综合征、神经轴突萎缩、多系统萎缩和阿尔茨海默病的治疗方法。该发明还提供了制备这些衍生物的方法，以及包括这些衍生物和药学上可接受的辅料的药物组合物。
• Pyrazoles as inhibitors of tumor necrosis factor
  申请人：Borcherding R. David

  公开号：US20060063796A1

  公开（公告）日：2006-03-23

  The present invention provides compounds of Formula (I) and ester prodrugs, pharmaceutically acceptable salts or solvates of such compounds; or ester prodrugs of such salts or solvates; pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF).

  本发明提供了式（I）的化合物和酯前药、这些化合物的药学上可接受的盐或溶剂；或这些盐或溶剂的酯前药；包括这些化合物的制药组合物，其制备以及它们在治疗能够通过抑制p38激酶和/或肿瘤坏死因子（TNF）调节的疾病状态中的药物应用。
• Piperazine and piperidine biaryl derivatives
  申请人：Lu Jian Rong

  公开号：US20070259879A1

  公开（公告）日：2007-11-08

  This invention relates to piperazine and piperidine biaryl compounds of Formula (I): or a pharmaceutically acceptable prodrug, salt, polymorph, solvate, enantiomer, diastereomer, racemate, mixture of stereoisomers thereof, or derivative thereof; and to processes for preparing the compounds or pharmaceutical compositions containing the same. The compounds and pharmaceutical compositions of the present invention are provided for use in the treatment of HIV infection and/or AIDS.

  本发明涉及公式（I）的哌嗪和哌啶双芳基化合物： 或其药物可接受的前药、盐、多晶形、溶剂化物、对映体、非对映体、外消旋体、其立体异构体混合物或衍生物；以及用于制备化合物或含有相同化合物的制药组合物的过程。本发明的化合物和制剂用于治疗HIV感染和/或艾滋病。
• Process for the preparation of oxazolidinones and method of use thereof
  申请人：Hollingsworth I. Rawle

  公开号：US20070265451A1

  公开（公告）日：2007-11-15

  A process for preparing N-(substituted)-C-(substituted methyl)-oxazolidinones, C-(substituted methyl)-oxazolidinones, and N-(substituted)-C-(substituted methyl)-oxazolidinones, preferably chiral, from optically active C-(protected oxymethyl)-oxazolidinones is described. The process can be used to produce combinatorial libraries of the above substituted oxazolidinones in a two or three step reaction comprising a plurality of reagents differing in numbers of carbons or particular substituted oxazolidinones. A number of substituted oxazolidinones produced using the above process have been discovered to have antimicrobial activity.

  本文介绍了一种从光学活性的C-（保护的氧甲基）-噁唑烷酮制备N-（取代）-C-（取代甲基）-噁唑烷酮、C-（取代甲基）-噁唑烷酮和N-（取代）-C-（取代甲基）-噁唑烷酮的方法，其中优选手性化合物。该方法可用于在包含多种碳数或特定取代噁唑烷酮的多种试剂的两步或三步反应中产生上述取代噁唑烷酮的组合库。使用上述方法生产的许多取代噁唑烷酮已被发现具有抗微生物活性。
• PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF
  申请人：Hollingsworth Rawle I.

  公开号：US20080146458A1

  公开（公告）日：2008-06-19

  Substituted oxazolidinone of the formula: wherein R 2 is alkyl selected from the group consisting of methyl, ethyl, and isopropyl moieties, are described. The compounds are antibacterial.

  描述了以下化学式的氧杂环丙酮类替代物：其中R2是选择自甲基，乙基和异丙基基团的烷基。这些化合物具有抗菌作用。